Evotec, a drug discoverer facing challenges under CEO Christian Wojczewski, confirmed receiving the unsolicited offer. The ...

Halozyme Therapeutics (NASDAQ:HALO) announced on Thursday its plans to acquire German drug developer Evotec SE ADR (NASDAQ:EVO) in a deal valued at approximately 2 billion euros ($2.10 billion), to ...

Halozyme intends to purchase all the shares of Evotec at 11 euros per share, which represents a premium of 27.5% to Evotec's last close price. U.S.-listed shares of Evotec were up 6.3%, while those of ...

German drugmaker Evotec is attracting takeover interest from U.S.-based Halozyme Therapeutics , Bloomberg News reported on Thursday.

Novo Nordisk (NVO) reportedly plans to phase out production of human insulin pens while it ramps up production of other ...

Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...